Coordonnées
Institut de cardiologie de Montréal
5000, rue Bélanger
Montréal H1T 1C8
Québec
T 514 376-3330
Jean-Claude.Tardif@icm-mhi.org
Axes de recherche
- Approches thérapeutiques
- Maladies cardiovasculaires
- Génomique
Description de la recherche
Dr Tardif’s research covers the molecular and genomic aspects of atherosclerosis and related diseases and also involves animal models, mechanistic and observational clinical studies as well as large international randomized clinical trials. Dr Tardif is or has been the international principal investigator or part of the study leadership of several large clinical trials in the field of atherosclerosis and other cardiovascular diseases.
Research axis
- Cardiovascular diseases
- Genomics
- Therapeutic approaches
Research description
Dr Tardif’s research covers the molecular and genomic aspects of atherosclerosis and related diseases and also involves animal models, mechanistic and observational clinical studies as well as large international randomized clinical trials. Dr Tardif is or has been the international principal investigator or part of the study leadership of several large clinical trials in the field of atherosclerosis and other cardiovascular diseases.
Publications
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC. N Engl J Med. 2015 3;373(23):2247-57.
- Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Tardif JC, Rhéaume E, Lemieux Perreault LP, Grégoire JC, Feroz Zada Y, Asselin G, Provost S, Barhdadi A, Rhainds D, L’Allier PL, Ibrahim R, Upmanyu R, Niesor EJ, Benghozi R, Suchankova G, Laghrissi-Thode F, Guertin MC, Olsson AG, Mongrain I, Schwartz GG, Dubé MP. Circ Cardiovasc Genet. 2015;8(2):372-82.
- CKM and LILRB5 are associated with serum levels of creatine kinase. Dubé MP, Zetler R, Barhdadi A, Brown AM, Mongrain I, Normand V, Laplante N, Asselin G, Zada YF, Provost S, Bergeron J, Kouz S, Dufour R, Diaz A, de Denus S, Turgeon J, Rhéaume E, Phillips MS,Tardif JC. Circ Cardiovasc Genet. 2014;7(6):880-6.
- Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Arsenault BJ, Boekholdt SM, Dubé MP, Rhéaume E, Wareham NJ, Khaw KT, Sandhu MS, Tardif JC. Circ Cardiovasc Genet. 2014;7(3):304-10.
- Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans. Arsenault BJ, Dubé MP, Brodeur MR, de Oliveira Moraes AB, Lavoie V, Kernaleguen AE, Guauque-Olarte S, Mathieu P, Pibarot P, Messika-Zeitoun D, Bossé Y, Rhainds D, Rhéaume E, Tardif JC. Arterioscler Thromb Vasc Biol. 2014;34(2):457-62